Quick Search 
Drugs of the Future
Register or sign in

Volume 45, Issue 4, April 2020, Pages 225-277
ALAS1 expression inhibitor, Treatment of acute porphyria.
Haddley, K.
Drugs Fut 2020, 45(4): 225
Summary | Full Text: PDF 
 Inarigivir soproxil.
Retinoic acid-inducible gene I protein (RIG-I) activator, Nucleotide-binding oligomerization domain-containing protein 2 (NOD2) activator, Treatment of chronic hepatitis B.
Nehra, V., Temesgen, Z.
Drugs Fut 2020, 45(4): 233
Summary | Full Text: PDF 
 Taking aim at a fast-moving target: targets to watch for SARS-CoV-2 and COVID-19.
Sorbera, L., Graul, A., Dulsat, C.
Drugs Fut 2020, 45(4): 239
Summary | Full Text: PDF 
 Research Fronts 2019: Clinical Medicine and Biological Sciences.
Research Fronts 2019 Collaborators
Drugs Fut 2020, 45(4): 245
Summary | Full Text: PDF 
 Pipeline on the move.
Torramade, E., Molas, G., Presa, A.
Drugs Fut 2020, 45(4): 255
Full Text: PDF 
 NME Digest.
Bofill, X., Cole, P., Fernandez-Forner, D., Torramade, E.
Drugs Fut 2020, 45(4): 267
Full Text: PDF 
 6th RSC/SCI Symposium on Ion Channels as Therapeutic Targets. Cambridge, UK – February 24-25, 2020.
Norman, P.
Drugs Fut 2020, 45(4): 273
Summary | Full Text: PDF 

© 2020 Clarivate Analytics. All rights reserved.
Copyright NoticeTerms of UsePrivacy StatementCookie Policy